Tecvayli monotherapy significantly reduces disease progression and mortality in relapsed or refractory multiple myeloma patients, showing a 71% reduction in progression risk and 40% in mortality risk.
Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...
Patients treated with ciltacabtagene autoleucel (cilta-cel; Carvykti) in the phase 3 CARTITUDE-4 trial (NCT04181827) achieved high rates of progression-free survival (PFS) at near ...
Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...
Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...
MedPage Today on MSN
Managing health-related quality of life in multiple myeloma
Palliative care that recognizes patient goals and values is essential, starting at diagnos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results